Brexpiprazole (Rexulti) for Dementia-Related Agitation
Start brexpiprazole at 0.5 mg once daily and titrate to a target dose of 2 mg daily over 2-4 weeks for elderly patients with agitation associated with Alzheimer's disease dementia. This is the FDA-approved dosing regimen that balances efficacy with safety in this vulnerable population 1.
Critical Safety Warning
Brexpiprazole carries a black box warning for increased mortality in elderly patients with dementia-related psychosis 1. This medication is FDA-approved specifically for agitation associated with Alzheimer's dementia, but NOT for dementia-related psychosis without agitation 1. The 2016 APA guideline emphasizes that antipsychotic benefits in dementia are "at best small" while adverse effects including mortality are consistently documented 2. Use only when nonpharmacologic interventions have failed and dangerous agitation threatens patient or caregiver safety.
Dosing and Titration Protocol
Starting Dose
- Begin at 0.5 mg once daily (oral, with or without food) 1
Titration Schedule
- Week 1-2: 0.5 mg daily
- Week 3-4: Increase to 1 mg daily
- Week 5+: Titrate to target dose of 2 mg daily based on response and tolerability 1
- Maximum dose: 3 mg daily (though 2 mg is the optimal therapeutic dose) 1
Dose Adjustments Required For:
Renal Impairment (CrCl <60 mL/min):
- Maximum 2 mg daily 1
Hepatic Impairment (Moderate to Severe):
- Maximum 2 mg daily 1
Drug Interactions:
- Strong CYP2D6 OR CYP3A4 inhibitors: Give half the usual dose 1
- Strong CYP2D6 AND CYP3A4 inhibitors together: Give one-quarter the usual dose 1
- Strong CYP3A4 inducers: Double the dose 1
Evidence for 2 mg Target Dose
The 2 mg dose demonstrates the optimal risk-benefit profile. Multiple 2026 meta-analyses consistently show that brexpiprazole 2 mg significantly reduces agitation on the Cohen-Mansfield Agitation Inventory (CMAI) with a mean difference of approximately -5 to -6 points versus placebo 3, 4, 5. The 3 mg dose offers minimal additional benefit while increasing adverse events 3. Specifically, 2 mg showed a treatment-emergent adverse event risk ratio of 1.20-1.33 compared to placebo, while serious adverse events were not significantly different 3.
Timeline Expectations
Expect 6-12 weeks for therapeutic effect. Brexpiprazole is a maintenance medication, NOT a PRN agent 1, 6. Clinical trials showed separation from placebo occurred between weeks 6-12 7. This delayed onset is a critical clinical consideration—patients and caregivers must understand this is not a rapid-acting intervention.
Monitoring Plan
Baseline Assessment
- Cardiovascular: Blood pressure (sitting and standing), heart rate, ECG if cardiac history
- Metabolic: Fasting glucose, HbA1c, lipid panel, weight, BMI
- Hematologic: CBC with differential (especially if history of leukopenia/neutropenia) 1
- Neurologic: Baseline movement disorder assessment (for tardive dyskinesia monitoring)
- Renal/Hepatic: Creatinine clearance, liver function tests
Ongoing Monitoring
Weeks 1-4 (Titration Phase):
- Weekly: Orthostatic vital signs, fall risk assessment
- Monitor for: Dizziness, somnolence, extrapyramidal symptoms 1
Weeks 4-12 (Efficacy Assessment):
- Every 2-4 weeks: Agitation severity (use standardized scale like CMAI if possible)
- Monitor for: Cerebrovascular events (stroke, TIA), neuroleptic malignant syndrome 1
Long-term (After Week 12):
- Every 3 months: Weight, metabolic parameters (glucose, lipids), movement disorder assessment
- Every 6 months: CBC if baseline abnormalities present 1
- Ongoing: Blood pressure, fall assessment at each visit
Red Flags Requiring Immediate Action
- Neuroleptic malignant syndrome: Fever, muscle rigidity, altered mental status, autonomic instability—STOP medication immediately 1
- Tardive dyskinesia: Involuntary movements—consider discontinuation 1
- Cerebrovascular events: New focal neurologic deficits—STOP medication 1
- Significant orthostatic hypotension: Systolic BP drop >20 mmHg—reduce dose or discontinue 1
Common Pitfalls to Avoid
Using as PRN medication: Brexpiprazole requires daily dosing for maintenance effect; it is explicitly NOT indicated for as-needed use 1, 6
Expecting rapid response: The 6-12 week timeline means you need bridging strategies for acute agitation (though recent 2025 guidelines suggest avoiding benzodiazepines and preferring oral quetiapine for acute severe agitation in elderly patients 8)
Inadequate nonpharmacologic trial: The 2016 APA guideline emphasizes nonpharmacologic approaches first 2. Document failed behavioral interventions before initiating antipsychotics
Ignoring drug interactions: CYP2D6 and CYP3A4 interactions are common—review medication list carefully 1
Continuing indefinitely without reassessment: Periodically attempt dose reduction or discontinuation to assess ongoing need, given mortality risks 2
Clinical Context
Brexpiprazole is the first and only FDA-approved medication specifically for agitation in Alzheimer's dementia 1, 6. However, the effect size is modest (Cohen's d = 0.30) 9, and there are no head-to-head trials comparing it to other antipsychotics 6. The 2025 geriatric emergency guidelines found that oral quetiapine had the best safety profile among antipsychotics for acute severe agitation in older adults 8, though these studies focused on emergency settings rather than chronic maintenance therapy.
The medication appears particularly effective in patients with severe agitation/aggression 7 and works equally well in patients with or without co-occurring psychosis 10. Pooled analysis of 621 participants showed CMAI improvement of -22.8 points with brexpiprazole versus -18.3 points with placebo over 12 weeks 9.